| Schedule of Segment Financial Information |
Schedule
of Segment Financial Information
| |
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
| |
|
Three Months Ended September 30,
|
|
|
Nine Months Ended September 30,
|
|
| |
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
| Net sales |
|
$ |
74,137 |
|
|
$ |
- |
|
|
$ |
74,137 |
|
|
$ |
- |
|
| Cost of sales |
|
|
(34,008 |
) |
|
|
- |
|
|
|
(34,008 |
) |
|
|
- |
|
| Gross profit |
|
|
40,129 |
|
|
|
- |
|
|
|
40,129 |
|
|
|
- |
|
| Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Research and development |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Clinical |
|
|
- |
|
|
|
- |
|
|
|
78,263 |
|
|
|
705,645 |
|
| Chemistry, manufacturing and controls and nonclinical |
|
|
35,811 |
|
|
|
36,274 |
|
|
|
96,068 |
|
|
|
320,104 |
|
| Personnel related |
|
|
107,483 |
|
|
|
468,113 |
|
|
|
565,250 |
|
|
|
1,377,614 |
|
| Total research and development |
|
|
143,294 |
|
|
|
504,387 |
|
|
|
739,581 |
|
|
|
2,403,363 |
|
| Selling, general and administrative |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Compliance |
|
|
409,501 |
|
|
|
344,290 |
|
|
|
1,541,650 |
|
|
|
1,472,750 |
|
| Legal |
|
|
926,945 |
|
|
|
107,694 |
|
|
|
2,030,000 |
|
|
|
453,897 |
|
| Marketing |
|
|
545,178 |
|
|
|
472,940 |
|
|
|
1,444,241 |
|
|
|
472,940 |
|
| Commercial readiness |
|
|
113,852 |
|
|
|
- |
|
|
|
242,799 |
|
|
|
- |
|
| Personnel related |
|
|
759,858 |
|
|
|
331,360 |
|
|
|
1,840,306 |
|
|
|
1,070,255 |
|
| Total selling, general and administrative |
|
|
2,755,334 |
|
|
|
1,256,284 |
|
|
|
7,098,996 |
|
|
|
3,469,842 |
|
| Interest income |
|
|
37,099 |
|
|
|
68,682 |
|
|
|
162,279 |
|
|
|
176,536 |
|
| Net loss |
|
$ |
(2,821,400 |
) |
|
$ |
(1,691,989 |
) |
|
$ |
(7,636,169 |
) |
|
$ |
(5,696,669 |
) |
|